Aldeyra Therapeutics, Inc.
ALDXNASDAQHealthcare● Active
$1.74
+$0.11(+6.75%)
Market Cap$104958658
P/E Ratio—
52W High$6.175
52W Low$1.07
Aldeyra Therapeutics, Inc. (ALDX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALDX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.03B) | ($0.06B) | ($0.04B) | ($0.06B) | ($0.06B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Change in Working Capital | ($0.01B) | $0.01B | $0.00B | ($0.00B) | $0.01B |
| Net Cash from Operations | ($0.03B) | ($0.04B) | ($0.03B) | ($0.06B) | ($0.04B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.04B) | ($0.10B) | $0.00B | ($0.09B) | $0.00B |
| Sales of Investments | $0.09B | $0.05B | $0.03B | $0.06B | $0.00B |
| Net Cash from Investing | $0.05B | ($0.04B) | $0.03B | ($0.03B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Net Cash from Financing | $0.00B | ($0.00B) | ($0.00B) | $0.00B | $0.19B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.03B) | ($0.04B) | ($0.03B) | ($0.06B) | ($0.04B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Aldeyra Therapeutics, Inc. data
About Aldeyra Therapeutics, Inc. (ALDX) Cash Flow Statement
Aldeyra Therapeutics, Inc. generated operating cash flow of ($0.03B) and free cash flow of ($0.03B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
ALDX · 4 questionsAldeyra Therapeutics, Inc. generated free cash flow of ($0.03B) for 2025, up 22.8% year-over-year.
ALDX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10